[4-[(E,3S)-3-hydroxy-4,4-dimethylpent-1-enyl]-2-methoxyphenyl] (3Z,6Z,9Z,12Z,15Z,18Z)-henicosa-3,6,9,12,15,18-hexaenoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [4-[(E,3S)-3-hydroxy-4,4-dimethylpent-1-enyl]-2-methoxyphenyl] (3Z,6Z,9Z,12Z,15Z,18Z)-henicosa-3,6,9,12,15,18-hexaenoate
• 化学式: C₃₅H₄₈O₄
• 分子量: 532.8
• InChiKey: ZAUWYYGECAXELP-HOMGFYQBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.3
• 重原子数：
  39
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGIC DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE L'ÉPILEPSIE ET DE MALADIES NEUROLOGIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014087331A2

  公开（公告）日：2014-06-12

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of epilepsy and neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, severe myoclonic epilepsy, Dravet's syndrome and severe myoclonic epilepsy in infants.